Novartis | NVS - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
AbbVie USD 3.84B 205M 2026-09
Amgen USD 1.72B 134M 2026-06
AstraZeneca USD 4.07B 1.73B 2026-09
Bausch Health Companies USD 834M 67M 2026-09
Biogen USD 752M 42.3M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Canopy Growth CAD 33.99M 2.83M 2026-06
Corcept Therapeutics USD 156.9M 28.85M 2026-06
Drreddys Laboratories INR 28.08B 13.61B 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Glaxosmithkline GBP 2.38B 264M 2026-09
J&J USD 6.25B 168M 2026-09
Merck USD 2.86B 25M 2026-09
Novartis USD 3.08B 163M 2026-09
Novartis USD 3.08B 58M 2026-09
Pacira USD 91.81M 7.93M 2026-06
Perrigo USD 3.28B 3.02B 2026-06
Pfizer USD 3.28B 132M 2026-09
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 43.3M 13.02M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.31B 325M 2026-09
Sanofi EUR 2.63B 140M 2026-06
Supernus Pharmaceuticals USD 133.64M 15.41M 2026-06
Zoetis USD 592M 4M 2026-06